Download MendeleyIdentification of Selective Imidazopyridine CSF1R Inhibitors.
Kane Jr., J.L., Asmussen, G., Batchelor, J., Cromwell, M., Fezoui, M., Fitzgerald, M., Giese, B., Gladysheva, T., Holley, S., Keefe, K., Kothe, M., Lam, B., Lim, S., Liu, J., Ma, L., Metz, M., Scholte, A.A., Shum, P., Wei, L., Woodworth, L., Edling, A.(2024) ACS Med Chem Lett 15: 722-730
- PubMed: 38746878 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1021/acsmedchemlett.4c00110
- Primary Citation Related Structures:
8W1L - PubMed Abstract:
Colony stimulating factor-1 receptor (CSF1R or c-FMS), a class III receptor tyrosine kinase expressed on members of the mononuclear phagocyte system (MPS), plays a key role in the proper functioning of macrophages, microglia, and related cells. Aberrant signaling through CSF1R has been associated with a variety of disease states, including cancer, inflammation, and neurodegeneration. In this Letter, we detail our efforts to develop novel CSF1R inhibitors. Drawing on previously described compounds, including GW2580 ( 4 ), we have discovered a novel series of compounds based on the imidazo[4,5- b ]pyridine scaffold. Initial structure-activity relationship studies culminated in the identification of 36 , a lead compound with potent CSF1R biochemical and cellular activity, acceptable in vitro ADME properties, and oral exposure in rat.
- Integrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States.
Organizational Affiliation:
